Literature DB >> 32483662

Prognostic effect of preoperative neutrophil-lymphocyte ratio is related with tumor necrosis and tumor-infiltrating lymphocytes in hepatocellular carcinoma.

Sang Yun Ha1, Sangjoon Choi1, Sujin Park1, Jong Man Kim2, Gyu-Seong Choi2, Jae-Won Joh2, Cheol-Keun Park3,4.   

Abstract

Blood neutrophil-to-lymphocyte ratio (NLR) is one index representing systemic inflammation, and high preoperative NLR has been suggested as an independent prognostic factor in HCC. However, the NLR cutoff value with the highest prognostic significance is not consistent, and the mechanism of this phenomenon remains unclear. Preoperative NLR was calculated from complete blood counts obtained before 14 days from operation day in 234 patients who underwent curative resection for primary HCC. The presence of tumor necrosis and degree of tumor-infiltrating lymphocytes (TILs) was determined histologically. High preoperative NLR (≥ 2.5) was observed in 28 (12.0%) of 234 HCCs and was significantly associated with younger age, larger tumor size, high Edmonson grade, microvascular invasion, major portal invasion, advanced AJCC T or BCLC stage, and low albumin level. Patients with high preoperative NLR showed shorter disease-specific survival (DSS) (p = 0.002) and a tendency for shorter recurrence-free survival (RFS) (p = 0.096). High preoperative NLR was associated with presence of tumor necrosis and low TIL. On multivariable analysis, preoperative NLR was an independent prognostic factor for DSS (hazard ratio: 2.050 (95% confidence interval 1.139-3.691), p = 0.017). However, the independent prognostic effect of NLR for DSS disappeared when tumor necrosis and TILs were added as co-variables. High NLR is an independent prognostic factor in patients with HCC who undergo curative resection. The prognostic effect of high NLR might originate from the prognostic effect of tumor necrosis or TILs.

Entities:  

Keywords:  Hepatocellular carcinoma; Necrosis; Neutrophil to lymphocyte ratio; Prognosis; Systemic inflammation; Tumor-infiltrating lymphocytes

Mesh:

Year:  2020        PMID: 32483662     DOI: 10.1007/s00428-020-02841-5

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  5 in total

1.  Down-regulation of TRPV6 Is Associated With Adverse Prognosis in Hepatocellular Carcinoma Treated With Curative Resection.

Authors:  Hyun Hee Koh; Sangjoon Choi; Cheol-Keun Park; Sang Yun Ha
Journal:  Cancer Genomics Proteomics       Date:  2022 Mar-Apr       Impact factor: 4.069

2.  Preoperative application of systemic inflammatory biomarkers combined with MR imaging features in predicting microvascular invasion of hepatocellular carcinoma.

Authors:  Xun Xu; Shuwen Sun; Qiuping Liu; Xisheng Liu; Feiyun Wu; Chong Shen
Journal:  Abdom Radiol (NY)       Date:  2022-03-10

3.  Tumor Necrosis Impacts Prognosis of Patients Undergoing Curative-Intent Hepatocellular Carcinoma.

Authors:  Tao Wei; Xu-Feng Zhang; Fabio Bagante; Francesca Ratti; Hugo P Marques; Silvia Silva; Olivier Soubrane; Vincent Lam; George A Poultsides; Irinel Popescu; Razvan Grigorie; Sorin Alexandrescu; Guillaume Martel; Aklile Workneh; Alfredo Guglielmi; Tom Hugh; Luca Aldrighetti; Itaru Endo; Timothy M Pawlik
Journal:  Ann Surg Oncol       Date:  2020-11-28       Impact factor: 5.344

4.  Prognostic Relevance of Neutrophil to Lymphocyte Ratio (NLR) in Luminal Breast Cancer: A Retrospective Analysis in the Neoadjuvant Setting.

Authors:  Antonino Grassadonia; Vincenzo Graziano; Laura Iezzi; Patrizia Vici; Maddalena Barba; Laura Pizzuti; Giuseppe Cicero; Eriseld Krasniqi; Marco Mazzotta; Daniele Marinelli; Antonella Amodio; Clara Natoli; Nicola Tinari
Journal:  Cells       Date:  2021-07-03       Impact factor: 7.666

5.  Correlation between Lymphocyte-to-Monocyte Ratio (LMR), Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR) and Tumor-Infiltrating Lymphocytes (TILs) in Left-Sided Colorectal Cancer Patients.

Authors:  Cieszymierz Gawiński; Wojciech Michalski; Andrzej Mróz; Lucjan Wyrwicz
Journal:  Biology (Basel)       Date:  2022-02-28
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.